We strive to provide patient-focused, personalized, multi-disciplinary care for gastrointestinal (GI) cancers. Our specialized providers in Medical Oncology (chemotherapy and targeted therapies), Surgical Oncology, Radiation Oncology, Pathology, Molecular Pathology, Radiology, Interventional Radiology, Nuclear Medicine, Gastroenterology (both Hepatology and Interventional Endoscopy), Nutrition, and Integrative Medicine work together to achieve the best outcomes for our patients. We have weekly GI cancer tumor boards, where our specialists come together to discuss patients and patient care.
Qualifications and experience
- Cancers, Cancers - Anal Cancer, Cancers - Colorectal Cancer, Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver), Cancers - Pancreatic Cancer, Digestive System, Digestive System - Gastroenterology (Stomach, Bowel, General GI Problems), Internal Medicine, Medical Oncology
- Languages spoken
Johns Hopkins University School of Medicine Program (2004)
Massachusetts General Hospital Program (1999)
Harvard Medical School (1998)
Massachusetts General Hospital Program (2001)
Williams College (MA) (1992)
- Clinical interest for patients
I am interested in Gastrointestinal Cancers (Colorectal, Pancreatic, Gastric, Esophageal, Hepatocellular, Gallbladder, Bile Ducts, Anal, GI, Stromal Tumors, Abdominal Carcinoma of Unknown Primary), Drug Development (Experimental Therapeutics) and Translational Research.
- Research interest for patients
My lab is mainly focused on using a personalized approach in developing new anticancer drugs for GI cancers. In particular, the lab uses a novel colorectal and pancreatic explant model whereby tumor tissue is obtained from the operating room and then placed directly into mice. Tumors are treated with new drugs and predictive biomarkers of sensitivity are discovered. These predictive markers are used in the clinic to pre-select patients that would most likely derive benefit from these new drugs. Additionally, these tumors are evaluated in orthotopic and metastatic models. Current anticancer drugs in the lab target Notch (g-secretase), Src, and hedgehog pathways.
- Volunteer activities
I have given GI cancer lectures at national meetings (ASCO, AACR) and at community cancer centers across the US and Europe. I also participate in grant, abstract, and manuscript reviews in my field.